In March 2025, the company declared new plans for just a direct-to-customer offering of its Wegovy weight loss drug. The company established a fresh pharmacy, known as NovoCare, which would demand prospects $499 per 30 days for entry to the drug, below 50 % the cost of the drug via other pharmaceutical distribution networks.[fifty three]are schedul